Although the cause of multiple myeloma is not known, research shows that genetic changes in the DNA of a single plasma cell ...

In spite of recent advances in the management of multiple myeloma, cure has been elusive, with efforts to improve long-term ...

The positive CHMP opinion is supported by data from the pivotal LINKER-MM1 trial, which evaluated linvoseltamab in adults with R/R MM. Earlier this month, the FDA accepted for review the Biologics ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...

The company previously teased the overall survival (OS ... of relapsed or refractory multiple myeloma." The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex (BVd) arm ...

The ongoing Phase 2 dose expansion portion is assessing the safety and anti-tumor activity of linvoseltamab, with the primary endpoint of objective response rate. Key secondary endpoints include ...

Patients who received cilta-cel had improvements in progression-free survival and overall survival if they had sustained a minimal residual disease-negative complete response or better for at least 1 ...

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today ...

About Multiple MyelomaAs the ... primary endpoint of objective response rate. Key secondary endpoints include duration of response, progression-free survival, rate of minimum residual disease ...

Despite these challenges, advances in the field are improving the outlook for people diagnosed with multiple myeloma. As evidence, the five-year overall survival rate in the United States has ...

Reports FY24 revenue $107.9M, consensus $121.7M. “2024 was a transformational year for Arcellx (ACLX) as our ASH data presentations for ...